Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 8/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19202569 | 0.84 | NR4A2 (0.63) | NR4A2BRD4ALDH1A1LMNAMAPT | |
| SCHEMBL1096698 | 0.83 | NR4A2 (0.44) | NR4A2GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL30525813 | 0.83 | NR4A2 (0.44) | NR4A2GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL17995258 | 0.80 | NR4A2 (0.69) | NR4A2HTTPOLBL3MBTL1BRD4 | |
| SCHEMBL1097177 | 0.79 | KMT2A (0.47) | NR4A2HTTPOLBMITFALDH1A1 | |
| SCHEMBL7501910 | 0.75 | ALDH1A1 (0.40) | NR4A2HTTPOLBMITFALDH1A1 | |
| SCHEMBL25742160 | 0.74 | LMNA (0.46) | NR4A2HTTPOLBMITFALDH1A1 | |
| SCHEMBL25742178 | 0.73 | ALDH1A1 (0.38) | NR4A2HTTPOLBL3MBTL1MITF | |
| SCHEMBL25742163 | 0.72 | LMNA (0.43) | NR4A2HTTPOLBMITFALDH1A1 | |
| SCHEMBL22790288 | 0.72 | SCN9A (0.41) | NR4A2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008040-B | Compounds for modulating FXR | 南京瑞捷医药科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-20220227745-A1 | Compounds For Modulating FXR | NANJING RUIJIE PHARMA TECH CO., LTD. (CN) | 2022-07-21 | — | — | US | disclosed |
| CN-114008040-A | Compounds for modulating FXR | 南京瑞捷医药科技有限公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020249064-A1 | COMPOUNDS FOR MODULATING FXR | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249064-A1 | COMPOUNDS FOR MODULATING FXR | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2020-12-17 | — | — | WO | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | NR4A2 570/4885GABRG2 1095/4885GABRB3 554/4885 |
| US-20220227745-A1 | Compounds For Modulating FXR | NR1H4, FXR1, FXR2 | NR4A2 126/4885GABRG2 454/4885GABRB3 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.